Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.44 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12999022 | 0.91 | NPC1 (0.53) | NR4A2LMNARECQLSMN1; SMN2HTT | |
| SCHEMBL2905845 | 0.90 | RXRA (0.54) | NR4A2LMNARECQLSMN1; SMN2HTT | |
| SCHEMBL15387353 | 0.89 | KMT2A (0.45) | NR4A2LMNARECQLSMN1; SMN2HTT | |
| SCHEMBL2904886 | 0.80 | RXRA (0.56) | NR4A2SMN1; SMN2HTTNPC1RAB9A | |
| SCHEMBL2910477 | 0.79 | LMNA (0.59) | NR4A2LMNARECQLSMN1; SMN2KMT2A | |
| SCHEMBL15387306 | 0.79 | NPC1 (0.48) | NR4A2SMN1; SMN2HTTNPC1RAB9A | |
| SCHEMBL2910569 | 0.78 | RXRA (0.63) | NR4A2LMNARECQLSMN1; SMN2HTT | |
| SCHEMBL12998989 | 0.77 | MAOA (0.60) | NR4A2SMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL2905853 | 0.77 | NR4A2 (0.62) | NR4A2SMN1; SMN2HTTNPC1RAB9A | |
| SCHEMBL12999016 | 0.77 | GCK (0.45) | NR4A2LMNARECQLSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220029-B1 | Benzamide compounds and their use as prostaglandin E4 receptor agonists | GLAXO GROUP LTD (GB) | 2013-11-20 | — | — | EP | claimed |
| US-8293798-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-10-23 | — | — | US | claimed |
| US-20100305166-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-12-02 | — | — | US | claimed |
| EP-2220029-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2010-08-25 | — | — | EP | claimed |
| WO-2009056582-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-05-07 | — | — | WO | claimed |
| EP-2220029-B1 | Benzamide compounds and their use as prostaglandin E4 receptor agonists | GLAXO GROUP LTD (GB) | 2013-11-20 | — | — | EP | disclosed |
| US-8293798-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-10-23 | — | — | US | disclosed |
| US-8293798-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-10-23 | — | — | US | disclosed |
| US-8293798-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-10-23 | — | — | US | disclosed |
| US-20100305166-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-12-02 | — | — | US | disclosed |
| US-20100305166-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-12-02 | — | — | US | disclosed |
| US-20100305166-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-12-02 | — | — | US | disclosed |
| EP-2220029-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009056582-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009056582-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305166-A1 | NOVEL COMPOUNDS | F12, C1R, RPS4X | NR4A2 557/4885LMNA 1702/4885RECQL 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.